Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2968 - Robotic anticancer drug compounding assist system for the preparation of injectable antineoplastic drugs


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP


Satohiro Masuda


Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385


S. Masuda, H. Watanabe, T. Irisa, K. Hata, A. Kumagai, C. Tanaka, N. Ozawa, K. Nakashima

Author affiliations

  • Department Of Pharmacy, Kyushu University Hospital, 812-8582 - FUKUOKA/JP


Abstract 2968


Many antineoplastic drugs are known to be mutagenic or teratogenic. Medical personnel handling antineoplastic drugs are at a high risk of occupational exposure. Therefore, in collaboration with Yaskawa Electric Corporation and Nikka Micron Co., Ltd, we developed the Cancer Drug Compounding Assist System (CDCAS). The CDCAS is an automated robotic system designed to efficiently facilitate the accurate preparation of drugs based on dose. In this study, we evaluated the CDCAS for accuracy, site contamination, and washing performance in the preparation of antineoplastic drugs.


5-Fluorouracil (5-FU; 600, 800, or 1200 mg) was added to 100 mL of saline; 5 samples of each formulation were prepared. The weight of the mixed drugs prepared using the CDCAS was compared to those prepared by a pharmacist, and the accuracy of each preparation was calculated in terms of percentage relative error. The acceptable variance was set at ± 5%. To test for contamination, cyclophosphamide (800 mg) was continuously added to 50 bags of 100 mL saline solution. Then, 25 locations inside the isolator were identified for measurement. Cyclophosphamide was collected from those sites by using a sampling sheet method. Twenty of those samples revealed adherence of 5-FU (300 µL) to the infusion bag surface. Ozonated water was used to wash 5-FU from the surface of the infusion bags. After the washing process, any 5-FU remaining on the infusion bag surface was recovered via a wiping method.


The average weight error ratio for the CDCAS and the pharmacist was −0.62% and 2.69%, respectively. Contamination of cyclophosphamide was confirmed at eight sites. Pollution of 5-FU was confirmed for two samples, and the removal rate was ≥ 99.9%.


Our study demonstrated that the CDCAS’s preparation accuracy and cleaning performance are within acceptable limits. Thus, the CDCAS could be used to potentially reduce occupational exposure to antineoplastic drugs.

Clinical trial identification

Legal entity responsible for the study

Satohiro Masuda




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.